2024-12-27 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

This report analyzes Eli Lilly and Co. (LLY), a pharmaceutical company, based on the provided data.  Note that this analysis is solely based on the provided information and may not reflect a complete picture.  Further research is always recommended before making any investment decisions.

**1. Performance Comparison with S&P 500 (VOO):**

Eli Lilly's cumulative return (577.98%) significantly outperforms the S&P 500's cumulative return (120.68%) over the analyzed period.  The difference is 457.3%, placing it at the 73.1st percentile of historical performance relative to the S&P 500 based on the provided range.  This indicates strong outperformance.

**2. Recent Price Movement:**

* **Closing Price:** $794.14
* **5-Day Moving Average:** $782.28
* **20-Day Moving Average:** $794.16
* **60-Day Moving Average:** $829.65

The price is slightly below the 20-day moving average and considerably below the 60-day moving average, suggesting a potential short-term downward trend.

**3. Technical Indicators and Expected Return:**

* **RSI (37.38):**  Suggests the stock is currently in oversold territory.
* **PPO (0.29):** Indicates a positive momentum, though relatively weak.
* **Relative Strength Change (20-day):** A positive change of 2.8 suggests a recent short-term upward trend.
* **Expected Return (111.9%):**  Projects a significant long-term (2+ years) outperformance compared to the S&P 500, assuming continued strong performance.  Given the already significant outperformance, this projection should be viewed with caution.  This high expected return may not be sustainable.


**4. Recent Earnings Analysis:**

The provided earnings data shows significant volatility in EPS.  While revenue generally shows growth, EPS fluctuates dramatically, including a significant negative EPS in both Q4 2023 and Q1 2024.  Notably, revenue growth is not consistently matched by EPS growth, suggesting factors impacting profitability beyond revenue generation.  Without further context (e.g., analyst expectations), it's impossible to assess whether these results represent "beats" or "misses."  The data shows a significant increase in EPS in Q2 2024 followed by a drop in Q3 2024.

**5. Financial Information Analysis:**

* **Revenue:** Shows relatively consistent revenue growth, with a slight dip in Q1 2024, indicating relatively consistent performance.
* **Profit Margin:** Remains consistently high (around 80%), indicating strong profitability.
* **Equity & ROE:** Fluctuates significantly, especially a negative ROE in Q3 2023 followed by higher ROE in subsequent quarters. This volatility needs further investigation to understand the underlying factors.

**6. News and Recent Issues:**

No recent news or analyst opinions are provided in the data. This section requires further information.

**7. Overall Analysis:**

LLY has shown exceptional historical performance compared to the S&P 500. The high expected return is noteworthy but should be considered alongside the volatility observed in recent earnings.  While revenue is generally strong and profit margins are consistently high, EPS volatility and fluctuations in ROE are concerning. The current price is slightly below recent moving averages, suggesting a potential short-term downward trend.  Further research is crucial, especially into the factors driving EPS volatility and the absence of recent news and analyst opinions.  The oversold RSI suggests a potential buying opportunity, but the overall picture requires more detailed investigation.

**8.  Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice.  Investment decisions should be based on thorough due diligence and consideration of your individual risk tolerance.
